By the PharmaTradz BD Team. Published November 2026.
Ask a distributor in the Gulf, Latin America, Southeast Asia or Africa how they plan to add ten new products next year, and most will give the same answer: in-license dossiers. Few regional companies can afford to develop a generic from scratch, and they don't need to. Hundreds of finished, approved dossiers sit with manufacturers who would rather license them out than register them in thirty countries themselves.
The dossiers that move fastest are those built to European standards: an EU-CTD dossier for a product made at an EU-GMP inspected site. This guide explains why that combination matters so much outside Europe, how licensing deals are usually structured, and what to check before you sign. It is written for business development teams on both sides of the table: the companies licensing in, and the manufacturers licensing out.
Why EU-CTD and EU-GMP open doors outside Europe
Most regulators in the rest of the world (often shortened to ROW) have far more applications than assessors. To cope, they increasingly rely on decisions already taken by agencies they trust. WHO is replacing the old idea of "stringent regulatory authorities" with a formal list of WHO-Listed Authorities. By 2025 that list included the European Medicines Agency and EU national regulators, the US FDA, the UK MHRA, Health Canada, Japan's PMDA, Swissmedic and others.
That reliance shows up in practical ways:
- Abridged or verification routes. Several Gulf, Asian and Latin American regulators offer shorter reviews when the same product is already approved in the EU or another reference market.
- WHO's collaborative registration procedure. For products approved by a WHO-Listed Authority, participating national regulators aim to decide within 90 working days of receiving complete documents, using the reference agency's own assessment and inspection reports.
- Tenders. Many ministry and hospital tenders score or require EU-GMP, a CoPP from a reference country, or both. Some special-import tenders accept unregistered products only if they are approved in a reference market.
- GMP recognition. An EU-GMP certificate, or an inspection by a PIC/S member, often shortens or replaces the local inspection of the manufacturing site.
The format helps too. A dossier written in the ICH CTD structure can be adapted to most national formats, including the ASEAN ACTD, without rewriting the science. That is why "EU-CTD, EU-GMP, CoPP available" is still the strongest opening line in a licensing offer.
Licensing in, licensing out: the usual deal structures
No two deals are identical, but most combine a few building blocks:
- Licence and supply. The most common model in ROW markets. The licensee gets the right to register and sell the product in named territories; the licensor manufactures and supplies finished packs, usually at an agreed transfer price with a minimum annual quantity.
- Dossier fee. A one-off or staged payment for the right to use the dossier, sometimes split into milestones: signature, submission, approval. Fees vary widely with the product, the territory and how much work the dossier still needs.
- Royalty or profit share. Less common for older generics, more common for complex or first-to-market products.
- Exclusivity. Usually per country, and usually tied to registration deadlines and minimum orders. If the licensee does not file or does not buy, exclusivity lapses.
- Technology transfer. Occasionally the licensee wants to manufacture locally later. That is a different, larger deal, but it helps to say early whether it is on the table.
Whoever holds the marketing authorisation in each country is a decision with long consequences. A licensee that holds the registration has more control and more value on its balance sheet; a licensor that keeps it protects the product if the partnership ends. Agree it before anyone files.
What to check before you sign
A dossier that is "approved in Europe" is not automatically ready for your market. These are the questions we see decide deals:
- Is it really approved, and where? Ask for the marketing authorisation numbers and check them in the national registers. A CoPP is the cleanest proof.
- Stability zone. European dossiers usually carry data for climatic zones I and II. Much of Asia, Africa and Latin America needs zone IVa or IVb data (hot and humid). If those studies are missing, add six to twelve months.
- Bioequivalence and the comparator. The BE study was almost certainly run against the EU reference product. Some regulators accept that; others want their own local comparator or a bridging study. Check before you pay.
- API documentation. Is there a CEP or an open-part DMF? Will the API source stay the same, and is it on the dossier?
- Site status. Current EU-GMP certificate, last inspection date, and any recent warning letters or non-compliance reports in EudraGMDP.
- Patents and data exclusivity in each target country, not just in Europe.
- Labelling and packs. Pack sizes, languages, serialisation requirements and the cost of country-specific artwork.
- Supply terms. Lead time, minimum batch, shelf life at dispatch, price review and what happens if the site has a problem.
For manufacturers licensing out
If you hold EU-CTD dossiers, the opportunity is bigger than most teams realise. Regional distributors want a short list of reliable partners, not a catalogue of 400 molecules. What wins deals:
- A one-page product sheet for each dossier: approvals, CoPP availability, stability zones covered, BE comparator, API source, pack sizes.
- Clear territory availability, so partners don't waste a call on a country you have already licensed.
- Honest timelines for zone IV stability, bridging studies and artwork.
- A sample licence and supply agreement ready to share.
You can list dossiers for out-licensing on PharmaTradz at no cost. Buyers searching by molecule and territory see them, and we pass on qualified enquiries: dossiers for licensing and list products, dossiers and partnerships.
For companies licensing in
Start from your market, not from a molecule list. Which products are tendered every year, which are in shortage, which have one or two registered suppliers? Our tender calendar and drug shortage radar are useful starting points. Then shortlist two or three dossiers per product and compare them on the checklist above, not on the dossier fee alone. The cheapest dossier is expensive if it needs a new stability programme.
If you are looking for specific dossiers, send us the molecules, strengths and territories. We match them with EU-GMP manufacturers that can license and supply: send your dossier requirement.
The bottom line
For most ROW markets, in-licensing an EU-CTD dossier from an EU-GMP site is still the quickest credible way to add products, because regulators and tender committees already trust the data behind it. The work is in the details: stability zones, comparators, API documents and supply terms. Check those early and the registration clock starts sooner.
This article is general business information, not legal or regulatory advice. Requirements differ by country and change over time; confirm them with the national regulator or a qualified regulatory adviser.
Frequently Asked Questions(FAQs)
What is an EU-CTD dossier?
A registration dossier in the ICH Common Technical Document format, prepared for and usually approved by a European regulator. It covers quality, non-clinical and clinical (typically bioequivalence) data in five modules and can be adapted to most national formats.
Why do ROW regulators value EU approval and EU-GMP?
Many rely on decisions from trusted agencies to speed up their own reviews. Approval in the EU, a CoPP from a reference country and an EU-GMP certificate can open abridged routes, shorten GMP inspections and score higher in tenders.
Can an EU dossier be used in ASEAN countries?
Usually yes, after conversion to the ASEAN ACTD format and with stability data for climatic zone IVb. Check local requirements for the bioequivalence comparator as well.
How are dossier licensing deals usually paid?
Most combine a dossier fee, often paid in milestones, with a supply agreement at an agreed transfer price and minimum quantities. Royalties are more common for complex or first-to-market products.
How do I list a dossier for out-licensing on PharmaTradz?
Use the free dossier listing form. Add the molecule, strengths, approvals, CoPP availability and available territories, and we pass on qualified enquiries from licensees.
